Plant Name: mammea siamensis
Taxonomic Information:
Plant ID: NPO32974
Plant Latin Name: mammea siamensis
Taxonomy Genus: Mammea
Taxonomy Family: Calophyllaceae
Plant External Links:
NCBI TaxonomyDB:
231913
Plant-of-the-World-Online:
428781-1
Used in Medicines:
Country/Region:
ThailandTraditional Medicine System:
Geographical Distribution:
Thailand; Myanmar; Cambodia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; | |
| GCGR; | |
| CDK2; FLT3; STK3; FLT4; CDC7; MINK1; GSK3B; CAMK2D; PRKCG; LYN; MATK; STK17A; PDPK1; RPS6KA3; JAK3; MET; PIM3; PIM2; PLK4; INSR; MAPK11; BLK; DAPK3; SGK2; MAP4K4; MAPK14; MAPK8; MAPK9; MKNK2; CDK1; MAP3K20; CSNK1A1; PRKACA; HIPK2; NTRK3; NTRK2; FLT1; PIM1; CLK4; NEK4; CSNK1D; TYRO3; PHKG2; RPS6KB1; PBK; CSNK1G3; KDR; CHEK2; MAP4K2; CLK2; BRSK1; FER; IRAK4; RET; CDK5; FGFR3; FES; PRKD2; DYRK3; AURKB; MAPK10; FRK; MARK3; SYK; FGFR1; DYRK1A; CSF1R; CSNK2A1; PRKD3; MELK; | |
| ALOX5; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family B GPCR) | GCGR | Glucagon receptor | P47871 | CHEMBL1985 |
| Protein Kinase | NTRK2 | Neurotrophic tyrosine kinase receptor type 2 | Q16620 | CHEMBL4898 |
| Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | CLK4 | Dual specificity protein kinase CLK4 | Q9HAZ1 | CHEMBL4203 |
| Protein Kinase | NEK4 | Serine/threonine-protein kinase Nek4 | P51957 | CHEMBL5819 |
| Protein Kinase | CSNK1D | Casein kinase I delta | P48730 | CHEMBL2828 |
| Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
| Protein Kinase | PHKG2 | Phosphorylase kinase gamma subunit 2 | P15735 | CHEMBL2349 |
| Protein Kinase | RPS6KB1 | Ribosomal protein S6 kinase 1 | P23443 | CHEMBL4501 |
| Protein Kinase | PBK | PDZ-binding kinase | Q96KB5 | CHEMBL4896 |
| Protein Kinase | CSNK1G3 | Casein kinase I isoform gamma-3 | Q9Y6M4 | CHEMBL5084 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CHEK2 | Serine/threonine-protein kinase Chk2 | O96017 | CHEMBL2527 |
| Protein Kinase | MAP4K2 | Mitogen-activated protein kinase kinase kinase kinase 2 | Q12851 | CHEMBL5330 |
| Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
| Protein Kinase | BRSK1 | BR serine/threonine-protein kinase 1 | Q8TDC3 | CHEMBL5650 |
| Protein Kinase | FER | Tyrosine-protein kinase FER | P16591 | CHEMBL3982 |
| Protein Kinase | IRAK4 | Interleukin-1 receptor-associated kinase 4 | Q9NWZ3 | CHEMBL3778 |
| Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
| Protein Kinase | CDK5 | Cyclin-dependent kinase 5 | Q00535 | CHEMBL4036 |
| Protein Kinase | FGFR3 | Fibroblast growth factor receptor 3 | P22607 | CHEMBL2742 |
| Protein Kinase | FES | Tyrosine-protein kinase FES | P07332 | CHEMBL5455 |
| Protein Kinase | PRKD2 | Serine/threonine-protein kinase D2 | Q9BZL6 | CHEMBL4900 |
| Protein Kinase | DYRK3 | Dual-specificity tyrosine-phosphorylation regulated kinase 3 | O43781 | CHEMBL4575 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
| Protein Kinase | FRK | Tyrosine-protein kinase FRK | P42685 | CHEMBL4223 |
| Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | CSF1R | Macrophage colony stimulating factor receptor | P07333 | CHEMBL1844 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | PRKD3 | Protein kinase C nu | O94806 | CHEMBL2595 |
| Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | CDC7 | Cell division cycle 7-related protein kinase | O00311 | CHEMBL5443 |
| Protein Kinase | MINK1 | Misshapen-like kinase 1 | Q8N4C8 | CHEMBL5518 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CAMK2D | CaM kinase II delta | Q13557 | CHEMBL2801 |
| Protein Kinase | PRKCG | Protein kinase C gamma | P05129 | CHEMBL2938 |
| Protein Kinase | LYN | Tyrosine-protein kinase Lyn | P07948 | CHEMBL3905 |
| Protein Kinase | MATK | Tyrosine-protein kinase CTK | P42679 | CHEMBL4175 |
| Protein Kinase | STK17A | Serine/threonine-protein kinase 17A | Q9UEE5 | CHEMBL4525 |
| Protein Kinase | PDPK1 | 3-phosphoinositide dependent protein kinase-1 | O15530 | CHEMBL2534 |
| Protein Kinase | RPS6KA3 | Ribosomal protein S6 kinase alpha 3 | P51812 | CHEMBL2345 |
| Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | PIM3 | Serine/threonine-protein kinase PIM3 | Q86V86 | CHEMBL5407 |
| Protein Kinase | PIM2 | Serine/threonine-protein kinase PIM2 | Q9P1W9 | CHEMBL4523 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MAPK11 | MAP kinase p38 beta | Q15759 | CHEMBL3961 |
| Protein Kinase | BLK | Tyrosine-protein kinase BLK | P51451 | CHEMBL2250 |
| Protein Kinase | DAPK3 | Death-associated protein kinase 3 | O43293 | CHEMBL2468 |
| Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
| Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | MAPK8 | c-Jun N-terminal kinase 1 | P45983 | CHEMBL2276 |
| Protein Kinase | MAPK9 | c-Jun N-terminal kinase 2 | P45984 | CHEMBL4179 |
| Protein Kinase | MKNK2 | MAP kinase signal-integrating kinase 2 | Q9HBH9 | CHEMBL4204 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAP3K20 | Mixed lineage kinase 7 | Q9NYL2 | CHEMBL3886 |
| Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
| Protein Kinase | PRKACA | cAMP-dependent protein kinase alpha-catalytic subunit | P17612 | CHEMBL4101 |
| Protein Kinase | HIPK2 | Homeodomain-interacting protein kinase 2 | Q9H2X6 | CHEMBL4576 |
| Protein Kinase | NTRK3 | NT-3 growth factor receptor | Q16288 | CHEMBL5608 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.083E-10 | 1.573E-08 | ALOX5, AURKB, BLK, CAMK2D, CDK1, CDK2, CDK5, CSNK1A1, CSNK1D, CSNK2A1, DYRK3, FER, FES, FGFR1, FLT3, FRK, GSK3B, IRAK4, JAK3, LMNA, LYN, MAP3K20, MAPK10, MAPK11, MAPK14, MAPK8, MAPK9, MARK3, MATK, MINK1, NTRK2, PDPK1, PHKG2, PIM1, PIM3, PLK4, PRKACA, PRKCG, PRKD2, PRKD3, RET, RPS6KA3, RPS6KB1, SGK2, STK3, SYK |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.098E-10 | 1.583E-08 | INSR, KDR, LYN, SYK, TYRO3 |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 4.281E-10 | 5.790E-08 | BLK, FER, FES, FRK, JAK3, LYN, MATK, SYK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.133E-70 | 5.805E-67 | AURKB, BLK, BRSK1, CAMK2D, CDC7, CDK1, CDK2, CDK5, CHEK2, CLK2, CLK4, CSF1R, CSNK1A1, CSNK1D, CSNK1G3, CSNK2A1, DAPK3, DYRK1A, DYRK3, FER, FES, FGFR1, FGFR3, FLT1, FLT3, FLT4, FRK, GSK3B, HIPK2, INSR, IRAK4, JAK3, KDR, LYN, MAP3K20, MAP4K2, MAP4K4, MAPK10, MAPK11, MAPK14, MAPK8, MAPK9, MARK3, MATK, MELK, MET, MINK1, MKNK2, NEK4, NTRK2, NTRK3, PBK, PDPK1, PHKG2, PIM1, PIM2, PIM3, PLK4, PRKACA, PRKCG, PRKD2, PRKD3, RET, RPS6KA3, RPS6KB1, SGK2, STK17A, STK3, SYK, TYRO3 |
| MF | GO:0003824; catalytic activity | GO:0050321; tau-protein kinase activity | 1.107E-09 | 1.444E-07 | BRSK1, CDK5, CSNK1D, GSK3B, PHKG2 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.976E-09 | 2.517E-07 | AURKB, CDK2, CDK5, CHEK2, CSNK2A1, DYRK1A, DYRK3, HIPK2, MAPK11, MAPK14 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 8.094E-09 | 9.631E-07 | FLT1, FLT3, FLT4, KDR |
| BP | GO:0009987; cellular process | GO:0000077; DNA damage checkpoint | 3.837E-07 | 3.496E-05 | BRSK1, CDK1, CDK2, CHEK2, MAP3K20, MAPK14 |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 4.482E-07 | 4.049E-05 | CSF1R, FER, FLT4, JAK3, MAPK14, MET, RPS6KB1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.208E-06 | 1.008E-04 | CYP1A2, CYP2D6, CYP3A4 |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 5.303E-06 | 4.052E-04 | FGFR1, FLT1, FLT4, INSR, LYN, NTRK2, NTRK3, RET, SYK |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 5.912E-06 | 4.470E-04 | FGFR3, FLT1, FLT3, LYN |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 6.523E-06 | 4.864E-04 | FGFR1, FLT1, FLT3, KDR, NTRK2 |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.088E-05 | 7.614E-04 | CSNK1D, FES, FGFR1, KDR, LYN, MAPK11, MAPK14, MAPK9, NTRK2, NTRK3, RET, RPS6KA3, STK3, SYK |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.306E-05 | 8.913E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010389; regulation of G2/M transition of mitotic cell cycle | 1.402E-05 | 9.483E-04 | AURKB, CDC7, CDK1, CDK2, CSNK1D, PLK4, PRKACA |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 1.748E-05 | 1.161E-03 | BRSK1, CDK5, CHEK2, GSK3B, MAP4K2, MAPK14, PDPK1, PRKACA, PRKD2, RPS6KA3, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 2.807E-05 | 1.757E-03 | KDR, MAPK14, PDPK1, PRKD2 |
| MF | GO:0003824; catalytic activity | GO:0016787; hydrolase activity | 2.955E-05 | 1.838E-03 | |
| MF | GO:0003824; catalytic activity | GO:0004697; protein kinase C activity | 3.286E-05 | 2.027E-03 | PRKCG, PRKD2, PRKD3 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 3.978E-05 | 2.400E-03 | AURKB, CDK1, CDK2 |
| BP | GO:0065007; biological regulation | GO:0010518; positive regulation of phospholipase activity | 4.316E-05 | 2.568E-03 | FGFR1, FGFR3, FLT1, PDPK1 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 4.488E-05 | 2.656E-03 | CSNK1D, MAPK10, MAPK8, MAPK9, PRKCG |
| MF | GO:0005488; binding | GO:0003677; DNA binding | 4.633E-05 | 2.727E-03 | |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.693E-05 | 2.733E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 4.712E-05 | 2.736E-03 | NTRK2, NTRK3, OPRD1, PRKD2, RET |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 7.142E-05 | 3.978E-03 | CDK1, CDK2, FER, MAPK8, MAPK9 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 7.794E-05 | 4.253E-03 | LYN, PDPK1, PRKCG, SYK, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0010628; positive regulation of gene expression | 8.070E-05 | 4.371E-03 | CDK1, CDK2, CHEK2, GSK3B, HIPK2, INSR, MAPK11, MAPK14, MAPK8, MAPK9, MET, NEK4, NTRK2, NTRK3, PIM2, PRKD2, RET, RPS6KA3, RPS6KB1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.363E-05 | 4.960E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.018E-04 | 5.332E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0071840; cellular component organization or biogenesis | GO:0044089; positive regulation of cellular component biogenesis | 1.328E-04 | 6.646E-03 | FER, FES, GSK3B, KDR, MAPK9, MET, NTRK2, NTRK3, PLK4 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 1.393E-04 | 6.918E-03 | CDK5, LYN, MINK1, NTRK2, PDPK1, PRKCG |
| BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 1.522E-04 | 7.481E-03 | GSK3B, JAK3, KDR, LYN, PDPK1, PRKD2, RET, SYK |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.670E-04 | 8.044E-03 | DAPK3, INSR, KDR, LYN, OPRD1, PRKACA, RET |
| BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 1.857E-04 | 8.829E-03 | AURKB, CDK1, CDK2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.901E-04 | 9.017E-03 | CAMK2D, CHEK2, CLK2, CSF1R, CSNK2A1, DAPK3, DYRK1A, FGFR1, FGFR3, FLT3, FLT4, KDR, MET, NTRK2, PLK4, RPS6KB1, STK3 |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.993E-04 | 9.331E-03 | AURKB, CDK1, CDK2, CDK5, CHEK2, CLK2, CSNK2A1, CYP2D6, DAPK3, DYRK1A, FGFR1, FRK, GSK3B, HIPK2, JAK3, LYN, MAPK14, MET, NTRK3, PBK, PDPK1, PRKCG, RPS6KA3 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.977E-18 | 1.125E-15 | CAMK2D, CDK1, CDK5, CHEK2, CSNK2A1, DAPK3, DYRK1A, GSK3B, HIPK2, MAPK8, PDPK1, PHKG2, PRKD2 |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 7.339E-16 | 1.598E-13 | AURKB, CLK2, CLK4, DYRK1A, DYRK3, MAPK10, MAPK14, PRKACA, PRKCG, RPS6KB1 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.542E-15 | 5.173E-13 | BLK, FER, FES, FRK, INSR, JAK3, KDR, LYN, MATK, SYK |
| MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 6.194E-15 | 1.215E-12 | BLK, DYRK1A, FER, FES, FRK, JAK3, LYN, MATK, MELK, SYK |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 8.926E-16 | 1.446E-13 | GSK3B, NTRK2, CAMK2D, PDPK1, NTRK3, MATK, IRAK4, MAPK14, MAPK10, MAPK11, MAPK9, RPS6KA3, MAPK8 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 4.418E-14 | 3.579E-12 | PRKCG, MAP4K2, NTRK2, MAPK14, STK3, MAPK10, MAPK11, MAPK9, RPS6KA3, MAPK8, MKNK2, PRKACA, FGFR3, MAP4K4, FGFR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.048E-13 | 4.346E-11 | LYN, GSK3B, SYK, CSNK2A1, MAPK14, MAPK10, MAPK11, MAPK9, MAPK8, CDK2, CDK1, PRKACA, JAK3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.987E-12 | 9.605E-11 | CSF1R, GSK3B, FLT1, SYK, PDPK1, INSR, FLT4, RPS6KB1, CDK2, KDR, SGK2, JAK3, FGFR3, MET, FGFR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.405E-12 | 5.688E-11 | PRKCG, CSF1R, FLT1, INSR, FLT4, MAPK14, MAPK11, PRKD3, KDR, PRKD2, FGFR3, MET, FGFR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.557E-12 | 9.605E-11 | PRKCG, CSF1R, FLT1, INSR, FLT4, MAPK10, MAPK9, MAPK8, KDR, PRKACA, FGFR3, MET, FGFR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.170E-10 | 4.668E-09 | PRKCG, RET, CSF1R, GSK3B, FLT3, DAPK3, MAPK10, MAPK9, MAPK8, CDK2, PRKACA, MET, FGFR3, FGFR1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.372E-10 | 2.519E-09 | MAPK10, MAPK11, MAPK9, RPS6KA3, MAPK8, CDK2, CDK1, MAPK14, PRKACA |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 2.040E-10 | 3.305E-09 | LYN, MAPK10, MAPK11, MAPK9, MAPK8, SYK, PDPK1, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 9.029E-11 | 2.089E-09 | MAPK10, PLK4, MAPK11, MAPK9, MAPK8, PDPK1, INSR, CDK2, MAPK14, SGK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 1.399E-10 | 2.519E-09 | MAPK10, GSK3B, MAPK9, MAPK8, RPS6KB1, PDPK1, INSR, MKNK2, PHKG2, PRKACA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.624E-09 | 2.193E-08 | MAPK10, PRKCG, MAPK11, GSK3B, MAPK9, CAMK2D, MAPK8, MAPK14, PRKACA |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.961E-09 | 4.583E-08 | MAPK10, PRKCG, MAPK11, MAPK9, CAMK2D, MAPK8, MAPK14, PRKACA |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.646E-09 | 5.717E-08 | PRKCG, MAPK11, CAMK2D, RPS6KB1, PDPK1, KDR, MAPK14, PRKACA, MET, FGFR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 3.803E-09 | 4.583E-08 | MAPK10, PRKCG, GSK3B, MAPK9, CAMK2D, MAPK8, CSNK2A1, CSNK1A1, PRKACA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.385E-09 | 5.717E-08 | MAPK10, PRKCG, GSK3B, MAPK9, MAPK8, FLT1, PDPK1, FLT4, KDR, MET |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 9.244E-09 | 8.319E-08 | MAPK10, GSK3B, MAPK9, RPS6KA3, MAPK8, RPS6KB1, PDPK1, INSR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.731E-08 | 1.476E-07 | MAPK10, MAPK11, MAPK9, MAPK8, PDPK1, ALOX5, IRAK4, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.621E-09 | 7.262E-08 | LYN, MAPK10, MAPK11, MAPK9, MAPK8, MAPK14, MET |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.976E-08 | 1.601E-07 | MAPK10, PRKCG, OPRD1, MAPK11, MAPK9, MAPK8, PDPK1, MAPK14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 5.929E-08 | 4.366E-07 | MAPK10, MAPK11, MAPK9, CAMK2D, MAPK8, MAPK14, PRKACA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 4.333E-08 | 3.343E-07 | MAPK10, PRKCG, GSK3B, MAPK9, CAMK2D, MAPK8, RPS6KB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 1.222E-07 | 8.607E-07 | MAPK10, PRKCG, MAPK11, MAPK9, MAPK8, MAPK14, PRKACA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 4.193E-07 | 2.613E-06 | MAPK10, MAPK11, MAPK9, CAMK2D, MAPK8, SYK, IRAK4, MAPK14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 3.411E-07 | 2.210E-06 | MAPK10, MAPK11, GSK3B, MAPK9, MAPK8, MAPK14 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.212E-07 | 1.493E-06 | RET, FLT3, NTRK3, MET, FGFR3, FGFR1 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 7.613E-07 | 4.405E-06 | MAPK10, MAPK11, CSF1R, MAPK9, MAPK8, SYK, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 8.012E-07 | 4.476E-06 | MAPK10, MAPK11, GSK3B, MAPK9, MAPK8, PDPK1, MAPK14 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.533E-06 | 1.282E-05 | MAPK10, MAPK11, MAPK9, MAPK8, PIM1, MAPK14 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.533E-06 | 1.282E-05 | MAPK10, PRKCG, MAPK9, MAPK8, RPS6KB1, PDPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 4.356E-07 | 2.614E-06 | MAPK10, MAPK11, MAPK9, MAPK8, IRAK4, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 5.001E-06 | 2.180E-05 | MAPK10, MAPK11, GSK3B, MAPK9, MAPK8, IRAK4, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.841E-06 | 1.353E-05 | PRKCG, CAMK2D, FLT1, RPS6KB1, INSR, MKNK2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 3.358E-06 | 1.511E-05 | MAPK10, MAPK11, MAPK9, MAPK8, IRAK4, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 3.005E-06 | 1.391E-05 | MAPK10, MAPK11, MAPK9, MAPK8, IRAK4, MAPK14 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.805E-05 | 6.963E-05 | MAPK11, GSK3B, MAPK14, FGFR3, JAK3, FGFR1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04925 | Aldosterone synthesis and secretion | 1.512E-05 | 5.974E-05 | PRKCG, CAMK2D, PRKD3, PRKD2, PRKACA |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.655E-06 | 1.303E-05 | MAPK10, MAPK11, MAPK9, MAPK8, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 6.622E-05 | 2.332E-04 | MAPK10, MAPK11, MAPK9, MAPK8, MAPK14 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 5.066E-05 | 1.824E-04 | MAPK11, GSK3B, MAPK9, PDPK1, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04340 | Hedgehog signaling pathway | 1.372E-06 | 7.409E-06 | GSK3B, CSNK1G3, CSNK1A1, CSNK1D, PRKACA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 9.708E-06 | 3.932E-05 | FER, CSNK2A1, INSR, MET, FGFR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 7.944E-05 | 2.681E-04 | MAPK10, MAPK9, MAPK8, CSNK2A1, CDK2, CDK1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 7.382E-06 | 3.066E-05 | MAPK10, MAPK11, MAPK9, MAPK8, MAPK14 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.082E-04 | 3.371E-04 | LYN, MAPK11, SYK, MAPK14, PRKACA |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.395E-04 | 4.036E-04 | LYN, SYK, CDK2, CDK1, PRKACA, JAK3 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 2.025E-05 | 7.628E-05 | MAPK10, MAPK11, MAPK9, MAPK8, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 5.114E-06 | 2.180E-05 | MAPK10, MAPK11, MAPK9, MAPK8, MAPK14 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.125E-04 | 3.437E-04 | RPS6KA3, CAMK2D, CDK2, CDK1, PRKACA |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.063E-04 | 5.761E-04 | MAPK10, MAPK9, MAPK8, PDPK1, LMNA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.802E-04 | 5.121E-04 | GSK3B, CSNK2A1, CDK2, IRAK4, JAK3 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.507E-04 | 6.882E-04 | MAPK10, PRKCG, MAPK9, MAPK8, CDK2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 2.929E-04 | 7.908E-04 | MAPK10, GSK3B, MAPK9, MAPK8, INSR |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.168E-04 | 3.505E-04 | GSK3B, CHEK2, CDK2, CDK1, CDC7 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.893E-04 | 1.201E-03 | RET, CSF1R, FLT1, KDR, FGFR3, MET |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 5.520E-04 | 1.335E-03 | CSF1R, FLT1, FLT3, FLT4, KDR, MET |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 8.409E-05 | 2.780E-04 | PRKCG, RPS6KA3, RPS6KB1, PDPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 6.871E-05 | 2.368E-04 | RPS6KB1, FLT3, PIM1, PIM2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 8.973E-05 | 2.907E-04 | PRKCG, MAPK11, KDR, MAPK14 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.870E-04 | 1.011E-03 | GSK3B, PDPK1, CDK2, FGFR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.026E-03 | 2.308E-03 | MAPK10, MAPK9, CAMK2D, MAPK8, PRKACA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 6.020E-04 | 1.434E-03 | PRKCG, GSK3B, CAMK2D, PRKACA |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 4.574E-04 | 1.140E-03 | LYN, PRKCG, SYK, RPS6KB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 9.564E-05 | 3.038E-04 | MAPK10, GSK3B, MAPK9, MAPK8 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 3.707E-04 | 9.844E-04 | PRKCG, CDK1, CSNK1D, PRKACA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04922 | Glucagon signaling pathway | 6.250E-04 | 1.467E-03 | CAMK2D, GCGR, PHKG2, PRKACA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.208E-04 | 2.131E-03 | PRKCG, CYP2D6, ALOX5, PRKACA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 4.574E-04 | 1.140E-03 | LYN, SYK, CSNK2A1, IRAK4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04720 | Long-term potentiation | 1.221E-04 | 3.597E-04 | PRKCG, RPS6KA3, CAMK2D, PRKACA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.118E-03 | 2.481E-03 | PRKCG, GSK3B, PDPK1, PRKACA |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 1.467E-03 | 3.212E-03 | GSK3B, CDK5, FES, MET |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.564E-03 | 5.128E-03 | MAPK11, CAMK2D, MAPK14, PRKACA |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 3.475E-05 | 1.279E-04 | MAPK10, MAPK9, MAPK8, INSR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 3.190E-03 | 6.009E-03 | GSK3B, MAPK8, CHEK2, PRKACA, JAK3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 5.153E-03 | 9.379E-03 | PRKCG, CAMK2D, PHKG2, PRKACA |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.153E-03 | 9.379E-03 | CSF1R, FLT1, FLT3, MET |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04911 | Insulin secretion | 4.321E-03 | 8.046E-03 | PRKCG, CAMK2D, PRKACA |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.812E-03 | 5.424E-03 | LYN, GSK3B, SYK |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.109E-03 | 4.496E-03 | MAPK10, MAPK9, MAPK8 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 2.812E-03 | 5.424E-03 | MAPK11, IRAK4, MAPK14 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 2.202E-03 | 4.633E-03 | PRKCG, CAMK2D, PRKACA |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.931E-03 | 4.171E-03 | RPS6KB1, INSR, PRKACA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 2.496E-03 | 5.054E-03 | MAPK10, MAPK9, MAPK8 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04971 | Gastric acid secretion | 2.923E-03 | 5.571E-03 | PRKCG, CAMK2D, PRKACA |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04115 | p53 signaling pathway | 2.395E-03 | 4.912E-03 | CHEK2, CDK2, CDK1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.395E-03 | 4.912E-03 | CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.812E-03 | 5.424E-03 | CYP2D6, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.442E-04 | 2.154E-03 | ALOX5, INSR, PRKACA |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.538E-04 | 1.140E-03 | PRKCG, PDPK1, INSR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.553E-03 | 9.996E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | RPS6KB1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | GCGR; INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | GCGR; INSR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; MAPK14; ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; INSR; OPRD1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; FLT1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; CDK2; KDR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | GCGR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPK8; NTRK2; RET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | GCGR; INSR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; FLT1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | GCGR; INSR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MAPK14; ALOX5; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | PIM2; FGFR3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1; |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Mesothelioma | C45 | MARK3; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| NA: NA | Metastatic hormone refractory prostate cancer | NA | LYN; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; CDK2; MAPK8; AURKB; SYK; KDR; FGFR1; FLT3; CHEK2; PIM2; FLT4; FGFR3; NTRK3; MELK; RET; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
| C00-D49: Neoplasms | Advanced or metastatic renal cell cancer | C64 | FGFR3; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; RET; |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; FGFR3; GSK3B; |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; |
| P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FLT1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CDK2; FLT3; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | FGFR1; PDPK1; INSR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; CAMK2D; OPRD1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PIM2; MAPK14; IRAK4; ALOX5; |
| NA: NA | Inflammatory diseases | NA | MAPK14; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; FLT4; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MAPK14; ALOX5; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; LYN; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; ALOX5; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Bone disease | M00-M99 | LYN; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | MAPK8; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; KDR; FLT3; INSR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | FLT1; |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GCGR; INSR; GSK3B; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK2; CDK1; MAPK9; SYK; KDR; FGFR1; CSNK2A1; RPS6KB1; FLT3; CHEK2; PDPK1; FLT4; MAPK14; FLT1; FGFR3; RET; GSK3B; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SYK; CDC7; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; KDR; FLT4; FGFR3; |
| I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1; |
| NA: NA | Rheumatold arthritis | NA | MAPK14; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| C00-D49: Neoplasms | Retinoblastoma | C69.2 | FGFR3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; CAMK2D; OPRD1; MAPK14; ALOX5; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
